Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a gut hormone and amino acid combo prevent low blood sugar in diabetes?

NCT ID NCT06881472

Knowledge-focused Sponsor: Asger Lund, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at how two substances—GIP, a natural gut hormone, and alanine, an amino acid from protein—work together to release glucagon, a hormone that raises blood sugar. Researchers tested 10 people with and without type 1 diabetes to see if combining GIP and alanine boosts glucagon more than either alone. The goal is to understand how this might protect against low blood sugar in type 1 diabetes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Glucose-dependent Insulinotropic Polypeptide (GIP) and alanine
What this could lead to
If successful, this research could point toward new ways to help people with type 1 diabetes avoid dangerously low blood sugar by boosting glucagon release.
What could go wrong
This is a very small, early-stage study with only 10 participants, so results may not apply broadly. It is designed to gather knowledge, not to test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

10 people

The number who actually took part.

Started

Jan 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Caucasian ethnicity * Age between 18 and 70 years * T1D (diagnosed according to the criteria of the World Health Organization) with HbA1c \<69 mmol/mol (\<8.5%) * Body mass index between 20-27 kg/m2 * T1D duration of 2-20 years * C-peptide negative (arginin-stimulated C-peptide ≤ 100 pmol/l) * Treatment with a stable basal-bolus or insulin pump regimen for ≥3 months * Informed and written consent Exclusion Criteria: * Anaemia (haemoglobin below normal range) * Late microvascular complications except mild nonproliferative retinopathy * Liver disease (alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) \>2 times normal values) or history of hepatobiliary disorder * Treatment with any glucose-lowering drugs beside insulin * Active or recent (within 5 years) malignant disease * Active tobacco smoking / use * Any condition considered incompatible with participation by the investigators

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetes

Contacts and locations

Locations

  • Gentofte Hospital

    Hellerup, 2900, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.